What Analysts Are Saying About Inspire Medical Systems Stock
In the latest quarter, 5 analysts provided ratings for Inspire Medical Systems (NYSE:INSP), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Inspire Medical Systems, presenting an average target of $229.0, a high estimate of $285.00, and a low estimate of $170.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.03%.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Inspire Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Block | Stifel | Lowers | Hold | $170.00 | $210.00 |
| Bob Hopkins | B of A Securities | Lowers | Neutral | $185.00 | $225.00 |
| Adam Maeder | Piper Sandler | Raises | Overweight | $255.00 | $250.00 |
| Shagun Singh | RBC Capital | Announces | Outperform | $285.00 | - |
| Anthony Petrone | Mizuho | Maintains | Buy | $250.00 | $250.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Inspire Medical Systems's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Get to Know Inspire Medical Systems Better
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Inspire Medical Systems's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Inspire Medical Systems displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 28.24%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Inspire Medical Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -6.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Inspire Medical Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.72%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Inspire Medical Systems's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Inspire Medical Systems's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.